Teva gets OK for P&G copycat

Teva Pharmaceutical Industries got the FDA's thumbs up for its version of the Procter & Gamble drug Actonel. The osteoporosis remedy has annual U.S. sales of $1 billion, and Teva will get first-out-of-the-gate marketing exclusivity for 180 days.

Not that Teva will sell the drug yet. It and P&G have been in a dispute over Actonel's patent. The case went to trial in late 2006 but has dragged on, with no decision reached. As part of that litigation, Teva agreed to give P&G 30 days notice before it markets Actonel; that notice hasn't yet been given.

- see Teva's press release
- read the report from the Cincinnati Business Journal

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.